Bilayer tablet formulations
View Patent ↗The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.
1. A coated bilayer tablet that comprises: (1) a bilayer tablet core comprising two layers wherein the first layer comprises a metformin hydrochloride extended release formulation; and the second layer comprises a sodium dependent glucose transporter inhibitor (SGLT2) selected from canagliflozin, dapagliflozin, dapagliflozin (S) propylene glycol hydrate, or dapagliflozin (R) propylene glycol hydrate; wherein the second layer is about 300 to about 400 mgs; (2) a first coating that coats the bilayer tablet core and optionally comprises saxagliptin; (3) a second coating that coats the first coating and optionally comprises saxagliptin; and (4) optionally a third coating that coats the second coating;
wherein at least one of the first coating and the second coating comprises saxagliptin; wherein the weight ratio between the first layer and the second layer is about 3.4:1 to about 4.8:1.
2. The coated bilayer tablet according to claim 1 wherein (1) the first layer comprises about 64-82% metformin hydrochloride, about 3-5% sodium carboxymethyl cellulose; about 15-30% hydroxypropyl methylcellulose; about 0.1-0.75% magnesium stearate; and about 0-2% silicon dioxide or 0-1.5% colloidal silicon dioxide, said percentages based on the total weight of the first layer; and the second layer comprises about 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 14-18% lactose anhydrous; about 50-80% microcrystalline cellulose; about 0-20% pregelatinized starch; about 0-20% mannitol; about 0-15%hydroxypropyl cellulose; about 2-6% crospovidone; about 0.5-2.5% silicon dioxide; and about 0.5-2% magnesium stearate, said percentages based on the total weight of the second layer; (2) the first coating comprises a polyvinyl alcohol based polymer; (3) the second coating comprises saxagliptin and a polyvinyl alcohol based polymer; and (4) the third coating comprises a polyvinyl alcohol based polymer.
3. The coated bilayer tablet according to claim 1 wherein (1) the first layer comprises about 67-71% metformin hydrochloride, about 3-5% sodium carboxymethyl cellulose, about 25-29% hydroxypropyl methylcellulose, and about 0.1-0.75% magnesium stearate, said percentages based on the total weight of the first layer; and the second layer comprises:
(A) about 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate: about 14-18% lactose anhydrous; about 72-80% microcrystalline cellulose; about 2-6% crospovidone;
about 0.5-2.5% silicon dioxide; and about 0.5-1.5% magnesium stearate, said percentages based on the total weight of the second layer;
(B) about 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 14-18% lactose anhydrous; about 50-70% microcrystalline cellulose; about 10-22% pregelatinized starch; about 2-6% crospovidone; about 0.5-2.5% silicon dioxide; and about 0.5-1.5% magnesium stearate, said percentages based on the total weight of the second layer;
(C) about 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 14-18% lactose anhydrous; about 60-70% microcrystalline cellulose; about 5-15% hydroxypropyl cellulose; about 2-6% crospovidone; about 0.5-2.5% silicon dioxide; and about 0.5-1.5% magnesium stearate, said percentages based on the total weight of the second layer; or
(D) about 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 14-18% lactose anhydrous; about 55-65% microcrystalline cellulose; about 10-20% mannitol;
about 2-6% crospovidone; about 0.5-2.5% silicon dioxide; and about 0.5-1.5% magnesium stearate, said percentages based on the total weight of the second layer;
(2) the first coating comprises polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide;
(3) the second coating comprises saxagliptin and polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide; and (4) the third coating comprises polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide.
4. The coated bilayer tablet according to claim 1 wherein (1) first layer comprises about 69% metformin hydrochloride, about 3.5% sodium carboxymethyl cellulose, about 27% hydroxypropyl methylcellulose, and about 0.48% magnesium stearate, said percentages based on the total weight of the first layer and the second layer comprises:
(A) about 0.8% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 16% lactose anhydrous; about 77% microcrystalline cellulose; about 4% crospovidone; about 1.5% silicon dioxide; and about 1% magnesium stearate, said percentages based on the total weight of the second layer;
(B) about 1.7% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 16% lactose anhydrous; about 76% microcrystalline cellulose; about 4% crospovidone; about 1.5% silicon dioxide; and about 1% magnesium stearate, said percentages based on the total weight of the second layer;
(C) about 3.4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 16% lactose anhydrous; about 74% microcrystalline cellulose; about 4% crospovidone; about 1.5% silicon dioxide; and about 1% magnesium stearate, said percentages based on the total weight of the second layer;
(D) about 1.7% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 16% lactose anhydrous; about 64% microcrystalline cellulose; about 13% pregelatinized starch; about 4% crospovidone; about 1.5% silicon dioxide; and about 1% magnesium stearate, said percentages based on the total weight of the second layer;
(E) about 1.7% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 16% lactose anhydrous; about 57% microcrystalline cellulose; about 19% pregelatinized starch; about 4% crospovidone; about 1.5% silicon dioxide; and about 1% magnesium stearate, said percentages based on the total weight of the second layer;
(F) about 1.7% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 16% lactose anhydrous; about 66% microcrystalline cellulose; about 10% hydroxypropyl cellulose;
about 4% crospovidone; about 1.5% silicon dioxide; and about 1% magnesium stearate, said percentages based on the total weight of the second layer; or
(G) about 1.7% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 16% lactose anhydrous; about 61% microcrystalline cellulose; about 15% mannitol; about 4% crospovidone; about 1.5% silicon dioxide; and about 1% magnesium stearate, said percentages based on the total weight of the second layer;
(2) the first coating comprises polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide; (3) the second coating comprises saxagliptin and polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide; and (4) the third coating comprises polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide.
5. The coated bilayer tablet according to claim 1 wherein (1) the first layer comprises about 72-82% metformin hydrochloride; about 3-5% sodium carboxymethyl cellulose; about 15-22% hydroxypropyl methylcellulose; about 0.75-1.25% silicon dioxide or about 0.25-0.75% colloidal silicon dioxide; and about 0.1-0.6% magnesium stearate, said percentages based on the total weight of the first layer; the second layer comprises:
(A) about 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 14-18% lactose anhydrous; about 72-80% microcrystalline cellulose; about 2-6% crospovidone; about 0.5-2.5% silicon dioxide; and about 0.5-1.5% magnesium stearate, said percentages based on the total weight of the second layer;
(B) about 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 14-18% lactose anhydrous; about 50-70% microcrystalline cellulose; about 10-22% pregelatinized starch; about 2-6.00% crospovidone; about 0.5-2.5% silicon dioxide; and about 0.5-1.5% magnesium stearate, said percentages based on the total weight of the second layer;
(C) about 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 14-18% lactose anhydrous; about 60-70% microcrystalline cellulose; about 5-15% hydroxypropyl cellulose; about 2-6% crospovidone; about 0.5-2.5% silicon dioxide; and about 0.5-1.5% magnesium stearate, said percentages based on the total weight of the second layer; or
(D) about 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 14-18% lactose anhydrous; about 55-65% microcrystalline cellulose; about 10-20% mannitol; about 2-6% crospovidone; about 0.5-2.5% silicon dioxide; and about 0.5-1.5% magnesium stearate, said percentages based on the total weight of the second layer;
(2) the first coating comprises polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide; (3) the second coating comprises saxagliptin and polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide; and (4) the third coating comprises polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide.
6. The coated bilayer tablet according to claim 1 wherein (1) the first layer comprises about 76.6% metformin hydrochloride; about 3.84% sodium carboxymethyl cellulose; about 18% hydroxypropyl methylcellulose; about 0.75-1.25% silicon dioxide or about 0.25-0.75% colloidal silicon dioxide; and about 0.53% magnesium stearate, said percentages based on the total weight of the first layer; the second layer comprises:
(A) about 0.8% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 16% lactose anhydrous; about 77% microcrystalline cellulose; about 4% crospovidone; about 1.5% silicon dioxide; and about 1% magnesium stearate, said percentages based on the total weight of the second layer;
(B) about 1.7% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 16% lactose anhydrous; about 76% microcrystalline cellulose; about 4% crospovidone; about 1.5% silicon dioxide; and about 1% magnesium stearate, said percentages based on the total weight of the second layer;
(C) about 3.4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate, about 16% lactose anhydrous; about 74% microcrystalline cellulose; about 4% crospovidone; about 1.5% silicon dioxide; and about 1% magnesium stearate, said percentages based on the total weight of the second layer;
(D) about 1.7% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 16% lactose anhydrous; about 64% microcrystalline cellulose; about 13% pregelatinized starch; about 4% crospovidone; about 1.5% silicon dioxide; and about 1% magnesium stearate, said percentages based on the total weight of the second layer;
(E) about 1.7% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 16% lactose anhydrous; about 57% microcrystalline cellulose; about 19% pregelatinized starch; about 4% crospovidone; about 1.5% silicon dioxide; and about 1% magnesium stearate, said percentages based on the total weight of the second layer;
(F) about 1.7% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 16% lactose anhydrous; about 66% microcrystalline cellulose; about 10% hydroxypropyl cellulose; about 4% crospovidone; about 1.5% silicon dioxide; and about 1% magnesium stearate, said percentages based on the total weight of the second layer; or
(G) about 1.7% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 16% lactose anhydrous; about 61% microcrystalline cellulose; about 15% mannitol; about 4% crospovidone; about 1.5% silicon dioxide; and about 1% magnesium stearate, said percentages based on the total weight of the second layer;
(2) the first coating comprises polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide; (3) the second coating comprises saxagliptin and polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide; and (4) the third coating comprises polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide.
7. A coated bilayer tablet that comprises: (1) a bilayer tablet core comprising two layers wherein the first layer comprises a metformin hydrochloride extended release formulation comprising 40-82% metformin hydrochloride, about 3-5% sodium carboxymethyl cellulose; about 15-40% hydroxypropyl methylcellulose; about 0.1-0.75% magnesium stearate; and about 0-2% silicon dioxide or 0-1.5% colloidal silicon dioxide, said percentages based on the total weight of the first layer; and the second layer comprises about 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 14-18% lactose anhydrous; about 50-80% microcrystalline cellulose; about 2-6% crospovidone; about 0.5-2.5% silicon dioxide; and about 0.5-2% magnesium stearate, said percentages based on the total weight of the second layer, wherein the second layer is about 300 to about 400 mgs; (2) a first coating that coats the bilayer tablet core comprising a polyvinyl alcohol based polymer; (3) a second coating that coats the first coating comprising saxagliptin and a polyvinyl alcohol based polymer; and (4) optionally a third coating that coats the second coating comprising a polyvinyl alcohol based polymer; wherein the weight ratio between the first layer and the second layer is of about 3.4:1 to about 4.8:1.
8. The coated bilayer tablet according to claim 1 wherein (1) the first layer comprises 40-87% metformin hydrochloride, about 1-10% sodium carboxymethyl cellulose, about 10-40% hydroxypropyl methylcellulose, and about 0.1-0.75% magnesium stearate, said percentages based on the total weight of the first layer.
9. The coated bilayer tablet according to claim 8 wherein the second layer comprises:
(A) about 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate: about 14-18% lactose anhydrous; about 72-80% microcrystalline cellulose; about 2-6% crospovidone; about 0.5-2.5% silicon dioxide; and about 0.5-1.5% magnesium stearate, said percentages based on the total weight of the second layer;
(B) about 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 14-18% lactose anhydrous; about 50-70% microcrystalline cellulose; about 10-22% pregelatinized starch; about 2-6% crospovidone; about 0.5-2.5% silicon dioxide; and about 0.5-1.5% magnesium stearate, said percentages based on the total weight of the second layer;
(C) about 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 14-18% lactose anhydrous; about 60-70% microcrystalline cellulose; about 5-15% hydroxypropyl cellulose; about 2-6% crospovidone; about 0.5-2.5% silicon dioxide; and about 0.5-1.5% magnesium stearate, said percentages based on the total weight of the second layer; or
(D) about 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 14-18% lactose anhydrous; about 55-65% microcrystalline cellulose; about 10-20% mannitol; about 2-6% crospovidone; about 0.5-2.5% silicon dioxide; and about 0.5-1.5% magnesium stearate, said percentages based on the total weight of the second layer.
10. The coated bilayer tablet according to claim 7 wherein the first layer further comprises 5-15% microcrystalline cellulose, said percentages based on the total weight of the first layer.
11. A coated bilayer tablet that comprises: (1) a bilayer tablet core comprising two layers wherein the first layer comprises a metformin hydrochloride extended release formulation comprising 40-87% metformin hydrochloride, about 1-10% sodium carboxymethyl cellulose, about 10-40% hydroxypropyl methylcellulose, and about 0.1-0.75% magnesium stearate, said percentages based on the total weight of the first layer; and the second layer comprises about 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate: about 14-18% lactose anhydrous; about 72-80% microcrystalline cellulose; about 2-6% crospovidone; about 0.5-2.5% silicon dioxide; and about 0.5-1.5% magnesium stearate, said percentages based on the total weight of the second layer; wherein the second layer is about 300 to about 400 mgs; (2) a first coating that coats the bilayer tablet core comprising a polyvinyl alcohol based polymer; (3) a second coating that coats the first coating comprising saxagliptin and a polyvinyl alcohol based polymer; and (4) a third coating that coats the second coating comprising a polyvinyl alcohol based polymer; wherein the weight ratio between the first layer and the second layer is of about 3.4:1 to about 4.8:1.
12. The coated bilayer tablet according to claim 11 wherein the first layer further comprises 5-15% microcrystalline cellulose, said percentages based on the total weight of the first layer.